港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

科倫博泰生物-B

285.400

-3.600-1.25%

成交量：81.19萬

成交額：2.33億

市值：647.86億

市盈率：-223.03

高：294.000

開：285.000

低：275.000

收：289.000

資料載入中...

總覽公司新聞公告

科倫博泰生物-B股價重挫12.69% 市值跌45億港元

每日賣空追蹤 | 科倫博泰生物-B 04月03日賣空量成交10.74萬股，賣空比例為12.16%

科倫博泰生物-B(06990)：中國證監會就公司H股全流通發出備案通知書

科倫博泰生物-B跌3.66% 股價跌破300港元大關

【華西醫藥】科倫博泰生物（6990）：商業化多點開花，核素偶聯藥物獲批臨牀

科倫博泰生物-B04月01日獲主力加倉899萬元

科倫博泰生物－Ｂ年報點評：商業化高歌猛進，看好靚麗數據催化

異動解讀 | 科倫博泰生物-B盤中大漲6.32%，或受2.31億港元大宗交易影響

異動解讀 | 科倫博泰生物-B盤中大漲6.32%，疑似受2.31億元大手交易影響

招銀國際：升科倫博泰生物-B目標價299.93港元對Sac-TMT內地商業化有信心

科倫博泰生物-B03月27日獲主力加倉736萬元

【券商聚焦】民生證券維持科倫博泰生物(06990)“推薦”評級看好2025年起獲批產品加速放量

《大行》招銀國際升科倫博泰(06990.HK)目標價299.93元對Sac-TMT內地商業化有信心

阿斯达克财经

港股異動 | 科倫博泰生物-B(06990)午後漲近13% 蘆康沙妥珠單抗有望迎來強勁增長

異動解讀 | 科倫博泰生物-B盤中大漲6.01%，里昂上調目標價至328.4港元

【大行評級｜里昂：上調科倫博泰生物-B目標價至328.4港元重申“跑贏大市”評級】里昂發表研究報告指，科倫博泰生物-B去年收入按年升25.5%至19.33億元，淨虧損按年收窄53.5%至2.67億元，均勝於預期。公司初步建立其銷售團隊，目標維持今年蘆康沙妥珠單抗(sac-TMT)藥物銷售達8億至10億元。該行指，進一步標籤擴充(label expansion)蘆康沙妥珠單抗及靶向人類表皮生長因子受體2(HER2)的抗體藥物偶聯物(ADC)獲批准等均是今年值得關注的重點。該行指，將公司今年及明年銷售預測分別下調4.5%及5%，其純利預測分別下調27.4%及24.1%。該行將其目標價由236.6港元上調至328.4港元，重申其評級為“跑贏大市”。

里昂：升科倫博泰生物-B(06990)目標價至328.4港元重申評級“跑贏大市”

智通财经网

科倫博泰生物-B(06990)：放射性核素偶聯藥物(RDC)SKB107新藥臨牀試驗申請獲國家藥品監督管理局批准

《業績》科倫博泰生物(06990.HK)全年虧損收窄至2.67億人民幣

阿斯达克财经

科倫博泰生物2024年虧損約2.67億元，同比減少53.5%

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/06990/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"06990","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06990\",,,,,undefined,":{"symbol":"06990","market":"HK","secType":"STK","nameCN":"科倫博泰生物-B","latestPrice":285.4,"timestamp":1744877289037,"preClose":289,"halted":0,"volume":811904,"delay":0,"floatShares":131000000,"shares":227000000,"eps":-1.2796556756154556,"marketStatus":"休市中","change":-3.6,"latestTime":"04-17 16:08:09","open":285,"high":294,"low":275,"amount":232778521,"amplitude":0.065744,"askPrice":286.4,"askSize":300,"bidPrice":285.4,"bidSize":300,"shortable":3,"etf":0,"ttmEps":-1.2796556756154556,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1745285400000},"marketStatusCode":7,"adr":0,"listingDate":1689004800000,"exchange":"SEHK","adjPreClose":289,"openAndCloseTimeList":[[1744853400000,1744862400000],[1744866000000,1744876800000]],"volumeRatio":1.0355934219983844,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06990\",,,,,undefined,":{"symbol":"06990","floatShares":131000000,"roa":"-3.41%","roe":"-9.46%","lyrEps":-1.279656,"volumeRatio":1.0355934219983844,"shares":227000000,"dividePrice":0,"high":294,"amplitude":0.065744,"preClose":289,"low":275,"week52Low":120.2,"pbRate":"18.42","psRate":"31.52","week52High":346,"institutionHeld":0,"latestPrice":285.4,"eps":-1.2796556756154556,"divideRate":0,"volume":811904,"delay":0,"ttmEps":-1.2796556756154556,"open":285,"prevYearClose":163.3,"prevWeekClose":302,"prevMonthClose":290.8,"prevQuarterClose":290.8,"fiveDayClose":280.8,"twentyDayClose":259.4,"sixtyDayClose":162.6},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"06990\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2525036168","title":"科倫博泰生物-B股價重挫12.69% 市值跌45億港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2525036168","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525036168?lang=zh_tw&edition=fundamental","pubTime":"2025-04-07 09:30","pubTimestamp":1743989422,"startTime":"0","endTime":"0","summary":"2025年04月07日早盘09时30分，科伦博泰生物-B股票出现异动，股价快速跳水12.69%。截至发稿，该股报269.800港元/股，成交量300股，换手率0.00%，振幅0.26%。资金方面，该股资金流入5.396万港元，流出2.706万港元。科伦博泰生物-B股票所在的生物技术行业中，整体跌幅为8.07%。科伦博泰生物-B公司简介：四川科伦博泰生物医药股份有限公司是一家主要从事创新药业务的研发、生产和销售的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025040709302294cd9a2f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025040709302294cd9a2f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06990","BK1161","LU0196878994.USD"],"gpt_icon":0},{"id":"2524506298","title":"每日賣空追蹤 | 科倫博泰生物-B 04月03日賣空量成交10.74萬股，賣空比例為12.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2524506298","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524506298?lang=zh_tw&edition=fundamental","pubTime":"2025-04-03 23:52","pubTimestamp":1743695569,"startTime":"0","endTime":"0","summary":"科伦博泰生物-B北京时间04月03日，跌0.77%，卖空量成交10.74万股，较上一交易日减少14.96%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250403235259a6aeb6ff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250403235259a6aeb6ff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0196878994.USD","06990","BK1161"],"gpt_icon":0},{"id":"2524266751","title":"科倫博泰生物-B(06990)：中國證監會就公司H股全流通發出備案通知書","url":"https://stock-news.laohu8.com/highlight/detail?id=2524266751","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524266751?lang=zh_tw&edition=fundamental","pubTime":"2025-04-03 22:18","pubTimestamp":1743689899,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦博泰生物-B(06990)发布公告，公司已收到中国证监会就实施H股全流通而发出日期为2025年4月3日的备案通知书。根据备案通知书，公司就合计2542.12万股内资股实施H股全流通向中国证监会作出的备案已经完成。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1274140.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0196878994.USD","BK1161","06990"],"gpt_icon":0},{"id":"2524406304","title":"科倫博泰生物-B跌3.66% 股價跌破300港元大關","url":"https://stock-news.laohu8.com/highlight/detail?id=2524406304","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524406304?lang=zh_tw&edition=fundamental","pubTime":"2025-04-03 13:05","pubTimestamp":1743656733,"startTime":"0","endTime":"0","summary":"2025年04月03日下午盘13时05分，科伦博泰生物-B股票出现波动，股价快速下跌3.66%。科伦博泰生物-B股票所在的生物技术行业中，整体跌幅为2.26%。科伦博泰生物-B公司简介：四川科伦博泰生物医药股份有限公司是一家主要从事创新药业务的研发、生产和销售的中国公司。消息层面，截至13时05分，《科伦博泰生物－Ｂ年报点评：商业化高歌猛进，看好靓丽数据催化》资讯为影响科伦博泰生物-B的重要信息。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250403130533aa2c57b5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250403130533aa2c57b5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0196878994.USD","06990","BK1161"],"gpt_icon":0},{"id":"2524425229","title":"【華西醫藥】科倫博泰生物（6990）：商業化多點開花，核素偶聯藥物獲批臨牀","url":"https://stock-news.laohu8.com/highlight/detail?id=2524425229","media":"华西研究","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524425229?lang=zh_tw&edition=fundamental","pubTime":"2025-04-03 07:35","pubTimestamp":1743636947,"startTime":"0","endTime":"0","summary":"华西医药根据公司公告，截至2024年12月31日止年度，公司收入19.33亿元人民币，同比增长25.5%；年度亏损2.67亿元，上年同期亏损5.74亿元；调整后年度亏损1.18亿元，上年同期亏损4.5亿元。同时，根据公告公司已于2025年3月25日收到NMPA批准SKB107新药临床试验申请的临床试验通知书。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250403074946a44bdcd9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250403074946a44bdcd9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1515","LU0196878994.USD","09939","06990","BK1161"],"gpt_icon":0},{"id":"2524162620","title":"科倫博泰生物-B04月01日獲主力加倉899萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2524162620","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524162620?lang=zh_tw&edition=fundamental","pubTime":"2025-04-01 16:17","pubTimestamp":1743495428,"startTime":"0","endTime":"0","summary":"04月01日, 科伦博泰生物-B股价涨5.91%，报收308.00元，成交金额2.64亿元，换手率0.66%，振幅11.28%，量比1.20。科伦博泰生物-B今日主力资金净流入899万元，上一交易日主力净流入1137万元。该股近5个交易日上涨21.57%，主力资金累计净流入629万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流出1815万元，其中净流出天数为10日。该股主力净额占比0.02%，港股市场排名216/2654。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250401170424a6abadc3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250401170424a6abadc3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0196878994.USD","BK1161","06990"],"gpt_icon":0},{"id":"2523969913","title":"科倫博泰生物－Ｂ年報點評：商業化高歌猛進，看好靚麗數據催化","url":"https://stock-news.laohu8.com/highlight/detail?id=2523969913","media":"华泰证券","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523969913?lang=zh_tw&edition=fundamental","pubTime":"2025-03-31 14:14","pubTimestamp":1743401672,"startTime":"0","endTime":"0","summary":"SKB264：TNBC及EGFRmt NSCLC3L+商业化，看好首年优秀表现我们看好SKB26425年销售可观：1)SKB264上市首月即覆盖1000余名患者，25年有望冲击10亿元销售收入；2)公司已覆盖全国Top100医院，成熟商业化队伍24年末已高达360人；3)EGFRmt NSCLC3L+与TNBC3L+两适应症参与2H25医保谈判，看好销售放量提速。此外，我们看好年内SKB264部分适应症或有OS数据读出潜力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250331143102a4482597&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250331143102a4482597&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","06990","LU0196878994.USD"],"gpt_icon":0},{"id":"1174212760","title":"異動解讀 | 科倫博泰生物-B盤中大漲6.32%，或受2.31億港元大宗交易影響","url":"https://stock-news.laohu8.com/highlight/detail?id=1174212760","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174212760?lang=zh_tw&edition=fundamental","pubTime":"2025-03-31 09:32","pubTimestamp":1743384767,"startTime":"0","endTime":"0","summary":"科伦博泰生物-B今日盘中股价大涨6.32%，引起市场广泛关注。这一显著涨幅可能与今早开盘前发生的一笔大宗交易有关。据汇港通讯报道，今日上午9时05分，科伦博泰生物-B出现一笔大宗交易，成交量为83.5万股，每股价格为276.65港元，总交易金额高达2.31亿港元。然而，目前尚不清楚这笔大宗交易背后的具体原因。投资者可能需要密切关注公司未来可能发布的相关公告或重大消息，以进一步了解这一交易的潜在影响。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["06990"],"gpt_icon":0},{"id":"1188858551","title":"異動解讀 | 科倫博泰生物-B盤中大漲6.32%，疑似受2.31億元大手交易影響","url":"https://stock-news.laohu8.com/highlight/detail?id=1188858551","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188858551?lang=zh_tw&edition=fundamental","pubTime":"2025-03-31 09:32","pubTimestamp":1743384765,"startTime":"0","endTime":"0","summary":"科伦博泰生物-B（06990）今日盘中股价大涨6.32%，引起市场关注。\n\n据汇港通讯报道，科伦博泰生物-B在今日开盘前出现一笔大手成交，涉资高达2.31亿元。具体成交信息显示，该笔交易于09:05:00进行，成交价格为276.65元，成交数量为83.5万股。这笔大额交易可能是引发股价上涨的主要原因。\n\n大手成交通常被视为机构投资者或大资金的操作，可能反映出投资者对公司前景的信心。这笔巨额交易可能吸引了更多投资者的关注，进而推动了股价的快速上涨。然而，投资者仍需谨慎，密切关注公司后续公告和市场动向。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 科伦博泰生物-B盘中大涨6.32%，疑似受2.31亿元大手交易影响","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["06990"],"gpt_icon":0},{"id":"2522347466","title":"招銀國際：升科倫博泰生物-B目標價299.93港元 對Sac-TMT內地商業化有信心","url":"https://stock-news.laohu8.com/highlight/detail?id=2522347466","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522347466?lang=zh_tw&edition=fundamental","pubTime":"2025-03-27 17:07","pubTimestamp":1743066420,"startTime":"0","endTime":"0","summary":"　　招银国际发布研报称，维持科伦博泰生物-B“买入”评级，对Sac-TMT在内地的全球开发和商业化保持信心，将目标价由227.88港元升至299.93港元。科伦博泰去年业绩强劲，主要得益于全球合作的里程碑付款以及创新管线的推进。截至目前，公司已有三个商业化资产，包括Sac-TMT、A140和A167。Sac-TMT已获得内地药监局对TNBC和3LEGFRm NSCLC的批准，其2L EGFRmNSCLC的NDA预计将在2025年下半年获批。该行预计公司将实现今年Sac-TMT的8亿至10亿元人民币销售目标。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2025-03-27/doc-inerauen0661728.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06990"],"gpt_icon":0},{"id":"2522229363","title":"科倫博泰生物-B03月27日獲主力加倉736萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2522229363","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522229363?lang=zh_tw&edition=fundamental","pubTime":"2025-03-27 16:27","pubTimestamp":1743064020,"startTime":"0","endTime":"0","summary":"03月27日, 科伦博泰生物-B股价涨12.32%，报收288.00元，成交金额1.97亿元，换手率0.54%，振幅14.90%，量比1.82。科伦博泰生物-B今日主力资金（超大单+大单）净流入736万元，上一交易日主力净流入293万元。该股近5个交易日上涨9.39%，主力资金累计净流入147万元；近20日主力资金累计净流出6281万元，其中净流出天数为12日。该股主力净额占比0.02%（主力资金净额/流通市值），港股市场排名267/2648。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250327180056a443cfcf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250327180056a443cfcf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","LU0196878994.USD","06990"],"gpt_icon":0},{"id":"2522346955","title":"【券商聚焦】民生證券維持科倫博泰生物(06990)“推薦”評級 看好2025年起獲批產品加速放量","url":"https://stock-news.laohu8.com/highlight/detail?id=2522346955","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522346955?lang=zh_tw&edition=fundamental","pubTime":"2025-03-27 16:10","pubTimestamp":1743063000,"startTime":"0","endTime":"0","summary":"2025年3月，芦康沙妥珠单抗获批第二项适应症，用于治疗EGFRmNSCLC，成为全球首款在肺癌领域获批上市的TROP2ADC药物，看好芦康沙妥珠单抗适应症扩展后销售加速放量。该行表示，2024年公司成功进入商业化阶段，该行看好2025年起获批产品加速放量，看好公司研发管线持续推进兑现，以及海外合作不断进展，带来长期高速增长动力。维持“推荐”评级。","market":"other","thumbnail":"https://static.szfiu.com/news/20250106/ODRhMzI4MWM5YTc2MTY1NjgxNGQwMTEwODUwOTcyNzQ0Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ODRhMzI4MWM5YTc2MTY1NjgxNGQwMTEwODUwOTcyNzQ0Mg==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1956081","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["161027","06990"],"gpt_icon":0},{"id":"2522140233","title":"《大行》招銀國際升科倫博泰(06990.HK)目標價299.93元  對Sac-TMT內地商業化有信心","url":"https://stock-news.laohu8.com/highlight/detail?id=2522140233","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522140233?lang=zh_tw&edition=fundamental","pubTime":"2025-03-27 14:29","pubTimestamp":1743056940,"startTime":"0","endTime":"0","summary":"招银国际发表研究报告指，科伦博泰去年业绩强劲，主要得益于全球合作的里程碑付款以及创新管线的推进。截至目前，公司已有三个商业化资产，包括Sac-TMT、A140和A167。A166的NDA已被接受用于2L和3L HER2+BC，预计将在 2025年下半年获批。该行预计公司将实现今年Sac-TMT的8亿至10亿元人民币销售目标。该行维持予其评级“买入”，对Sac-TMT在内地的全球开发和商业化保持信心，将目标价由227.88港元升至299.93港元。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20230904161537733_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20230904161537733_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/analysis/china-hot-topic-content.aspx?id=NOW.1428772&catg=4&source=AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["06990"],"gpt_icon":0},{"id":"2522665311","title":"港股異動 | 科倫博泰生物-B(06990)午後漲近13% 蘆康沙妥珠單抗有望迎來強勁增長","url":"https://stock-news.laohu8.com/highlight/detail?id=2522665311","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522665311?lang=zh_tw&edition=fundamental","pubTime":"2025-03-27 14:15","pubTimestamp":1743056106,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科伦博泰生物-B午后涨近13%，截至发稿，涨12.56%，报288.6港元，成交额1.19亿港元。里昂发布研报称，科伦博泰生物24年收入同比升25.5%至19.33亿元人民币，净亏损同比收窄53.5%至2.67亿元人民币，均胜于预期。开源证券则指出，科伦博泰生物药品销售收入主要是由芦康沙妥珠单抗自2024年11月22日在中国获批上市后贡献。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1268789.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06990","BK1161","LU0196878994.USD"],"gpt_icon":0},{"id":"1182418355","title":"異動解讀 | 科倫博泰生物-B盤中大漲6.01%，里昂上調目標價至328.4港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1182418355","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182418355?lang=zh_tw&edition=fundamental","pubTime":"2025-03-27 11:16","pubTimestamp":1743045412,"startTime":"0","endTime":"0","summary":"科伦博泰生物-B今日盘中大涨6.01%，引发市场关注。这波涨势主要受到里昂证券最新研究报告的推动，该报告对公司业绩表现给予积极评价，并大幅上调了目标价。根据里昂的研究报告，科伦博泰生物去年收入同比增长25.5%至19.33亿元，净亏损同比收窄53.5%至2.67亿元，均优于市场预期。该行将科伦博泰生物的目标价从236.6港元大幅上调至328.4港元，较当前股价有显著上涨空间，并重申\"跑赢大市\"评级。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 科伦博泰生物-B盘中大涨6.01%，里昂上调目标价至328.4港元","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["06990"],"gpt_icon":0},{"id":"2522439111","title":"【大行評級｜里昂：上調科倫博泰生物-B目標價至328.4港元 重申“跑贏大市”評級】里昂發表研究報告指，科倫博泰生物-B去年收入按年升25.5%至19.33億元，淨虧損按年收窄53.5%至2.67億元，均勝於預期。公司初步建立其銷售團隊，目標維持今年蘆康沙妥珠單抗(sac-TMT)藥物銷售達8億至10億元。該行指，進一步標籤擴充(label expansion)蘆康沙妥珠單抗及靶向人類表皮生長因子受體2(HER2)的抗體藥物偶聯物(ADC)獲批准等均是今年值得關注的重點。該行指，將公司今年及明年銷售預測分別下調4.5%及5%，其純利預測分別下調27.4%及24.1%。該行將其目標價由236.6港元上調至328.4港元，重申其評級為“跑贏大市”。","url":"https://stock-news.laohu8.com/highlight/detail?id=2522439111","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522439111?lang=zh_tw&edition=fundamental","pubTime":"2025-03-27 11:11","pubTimestamp":1743045118,"startTime":"0","endTime":"0","summary":"里昂发表研究报告指，科伦博泰生物-B去年收入按年升25.5%至19.33亿元，净亏损按年收窄53.5%至2.67亿元，均胜于预期。公司初步建立其销售团队，目标维持今年芦康沙妥珠单抗(sac-TMT)药物销售达8亿至10亿元。该行指，进一步标签扩充(label expansion)芦康沙妥珠单抗及靶向人类表皮生长因子受体2(HER2)的抗体药物偶联物(ADC)获批准等均是今年值得关注的重点。该行指，将公司今年及明年销售预测分别下调4.5%及5%，其纯利预测分别下调27.4%及24.1%。该行将其目标价由236.6港元上调至328.4港元，重申其评级为“跑赢大市”。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/27111149078884.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["06990","ADC"],"gpt_icon":0},{"id":"2522299458","title":"里昂：升科倫博泰生物-B(06990)目標價至328.4港元 重申評級“跑贏大市”","url":"https://stock-news.laohu8.com/highlight/detail?id=2522299458","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522299458?lang=zh_tw&edition=fundamental","pubTime":"2025-03-26 17:36","pubTimestamp":1742981760,"startTime":"0","endTime":"0","summary":"里昂发布研报称，科伦博泰生物-B去年收入同比升25.5%至19.33亿元人民币，净亏损同比收窄53.5%至2.67亿元人民币，均胜于预期。该行指，将公司今年及明年销售预测分别下调4.5%及5%，其纯利预测分别下调27.4%及24.1%。该行将其目标价由236.6港元上调至328.4港元，重申其评级为“跑赢大市”。报告提及，公司初步建立其销售团队，目标维持今年芦康沙妥珠单抗药物销售达8亿至10亿元人民币。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2025-03-26/doc-ineqyrfh5938593.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06990"],"gpt_icon":0},{"id":"2522021518","title":"科倫博泰生物-B(06990)：放射性核素偶聯藥物(RDC)SKB107新藥臨牀試驗申請獲國家藥品監督管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2522021518","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522021518?lang=zh_tw&edition=fundamental","pubTime":"2025-03-25 19:41","pubTimestamp":1742902872,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦博泰生物-B(06990)公布，公司已于2025年3月25日收到国家药品监督管理局药品审评中心批准SKB107新药临床试验申请的临床试验通知书。SKB107是由公司及西南医大附属医院核医学科共同开发的，以小分子作为靶向配体，搭配适宜的连接技术、螯合剂和治疗用放射性同位素而组成的新型RDC药物，拟用于治疗晚期实体瘤骨转移。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1267378.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","LU0196878994.USD","RDC","03347","BK1161","06990","BK1576","BK1583"],"gpt_icon":0},{"id":"2521732077","title":"《業績》科倫博泰生物(06990.HK)全年虧損收窄至2.67億人民幣","url":"https://stock-news.laohu8.com/highlight/detail?id=2521732077","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521732077?lang=zh_tw&edition=fundamental","pubTime":"2025-03-24 22:48","pubTimestamp":1742827680,"startTime":"0","endTime":"0","summary":"科伦博泰生物－Ｂ(06990.HK) 公布2024年度业绩，收入录得19.33亿人民币(下同)，按年增加25.5%；毛利12.74亿元，上升67.8%。亏损由上年度5.74亿元，收窄至2.67亿元，每股亏损1.2元。不派末期息。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-24 16:25。)过往派息公布日期派息事项派息内容2024/08/19中期业绩无派息2024/03/25末期业绩无派息2023/08/28中期业绩无派息AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20230904161537733_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20230904161537733_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1427438/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","LU0196878994.USD","06990"],"gpt_icon":0},{"id":"2521729137","title":"科倫博泰生物2024年虧損約2.67億元，同比減少53.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2521729137","media":"北京商报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521729137?lang=zh_tw&edition=fundamental","pubTime":"2025-03-24 20:58","pubTimestamp":1742821123,"startTime":"0","endTime":"0","summary":"北京商报讯（记者王寅浩）3月24日，科伦博泰生物-B发布2024年度业绩报告显示，2024年实现收入19.33亿元，同比增长25.5%；实现毛利约12.74亿元，同比增长67.8%；年度亏损约为2.67亿元，同比减少53.5%，调整后年度亏损约为1.18亿元，同比减少73.7%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202503243354485971.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202503243354485971.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","LU0196878994.USD","06990"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/06990\",params:#limit:5,,,undefined,":[{"date":"2025-03-24","symbol":"06990","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1742779800000,"name":null,"time":"盤後","dateTimestamp":1742745600000,"actualEps":null},{"date":"2024-08-19","symbol":"06990","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724031000000,"name":null,"time":"盤後","dateTimestamp":1723996800000,"actualEps":null},{"date":"2024-03-25","symbol":"06990","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1711330200000,"name":null,"time":"","dateTimestamp":1711296000000,"actualEps":null},{"date":"2023-08-28","symbol":"06990","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1693186200000,"name":null,"time":"","dateTimestamp":1693152000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"06990\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"06990\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.2941,"buy":0.7059,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.7059,"analysts":17,"updateTime":1744646400000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/06990\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"06990","date":"2025-04-17","current":-228.611836,"percent":0.03653,"low":-257.850518,"twenty":-159.44307,"median":-68.80487,"eighty":-45.06217,"high":-21.029201,"avg":-97.473315,"sd":62.021902,"marketCap":64862287200},"quantilePoints":[{"date":"2023-07-14","current":-21.13661,"twenty":-21.950454,"median":-21.915957,"eighty":-21.591449,"marketCap":14244687534},{"date":"2023-07-21","current":-23.970152,"twenty":-21.950454,"median":-21.798359,"eighty":-21.186829,"marketCap":16079230625},{"date":"2023-07-28","current":-25.171471,"twenty":-24.928642,"median":-21.953758,"eighty":-21.326081,"marketCap":16867005011},{"date":"2023-08-04","current":-23.795235,"twenty":-24.81024,"median":-23.425444,"eighty":-21.637654,"marketCap":15971316326},{"date":"2023-08-11","current":-25.354634,"twenty":-24.81024,"median":-23.323535,"eighty":-21.856149,"marketCap":16921892522},{"date":"2023-08-18","current":-27.290696,"twenty":-25.136334,"median":-23.811022,"eighty":-21.920213,"marketCap":18083628667},{"date":"2023-08-25","current":-27.955027,"twenty":-25.91111,"median":-24.066367,"eighty":-21.957062,"marketCap":18532979440},{"date":"2023-09-01","current":-41.23344,"twenty":-27.36684,"median":-24.766756,"eighty":-21.989236,"marketCap":16768455673},{"date":"2023-09-08","current":-41.179226,"twenty":-40.625811,"median":-24.994187,"eighty":-22.159386,"marketCap":16549260174},{"date":"2023-09-15","current":-42.756679,"twenty":-41.200358,"median":-25.354634,"eighty":-22.761005,"marketCap":17316444421},{"date":"2023-09-22","current":-42.808543,"twenty":-42.12743,"median":-25.915972,"eighty":-23.169807,"marketCap":17261645546},{"date":"2023-09-29","current":-41.568511,"twenty":-42.347449,"median":-27.197776,"eighty":-23.343916,"marketCap":16790375223},{"date":"2023-10-06","current":-41.914184,"twenty":-42.346401,"median":-27.481057,"eighty":-23.57336,"marketCap":16921892522},{"date":"2023-10-13","current":-45.021843,"twenty":-42.393899,"median":-34.166325,"eighty":-23.80155,"marketCap":18149387317},{"date":"2023-10-20","current":-39.509362,"twenty":-42.529229,"median":-40.304828,"eighty":-23.874674,"marketCap":15902633452},{"date":"2023-10-27","current":-41.923505,"twenty":-42.45246,"median":-40.317099,"eighty":-23.977981,"marketCap":16867093648},{"date":"2023-11-03","current":-44.17615,"twenty":-43.157759,"median":-40.968576,"eighty":-24.032126,"marketCap":17820594068},{"date":"2023-11-10","current":-48.451746,"twenty":-43.729096,"median":-41.213927,"eighty":-24.147781,"marketCap":19541278735},{"date":"2023-11-17","current":-48.422639,"twenty":-44.163404,"median":-41.246315,"eighty":-24.349478,"marketCap":19705675360},{"date":"2023-11-24","current":-47.973827,"twenty":-44.628759,"median":-41.529173,"eighty":-24.780872,"marketCap":19683755810},{"date":"2023-12-01","current":-50.941262,"twenty":-45.174782,"median":-41.90853,"eighty":-24.844962,"marketCap":20987969029},{"date":"2023-12-08","current":-50.880899,"twenty":-46.685504,"median":-41.9817,"eighty":-24.922954,"marketCap":20878371279},{"date":"2023-12-15","current":-53.058458,"twenty":-47.438439,"median":-42.172758,"eighty":-25.124621,"marketCap":21897630350},{"date":"2023-12-22","current":-55.272951,"twenty":-48.26932,"median":-42.355666,"eighty":-25.208104,"marketCap":22796331896},{"date":"2023-12-29","current":-54.398289,"twenty":-48.483234,"median":-42.389893,"eighty":-25.318001,"marketCap":22555216847},{"date":"2024-01-05","current":-54.305497,"twenty":-48.692055,"median":-42.518207,"eighty":-25.505631,"marketCap":22357940898},{"date":"2024-01-12","current":-58.852865,"twenty":-49.706536,"median":-42.808543,"eighty":-25.777515,"marketCap":24243022189},{"date":"2024-01-19","current":-48.649703,"twenty":-50.614438,"median":-43.44751,"eighty":-25.920835,"marketCap":20012549058},{"date":"2024-01-26","current":-45.202208,"twenty":-50.432693,"median":-43.523908,"eighty":-26.320623,"marketCap":18522019665},{"date":"2024-02-02","current":-38.832469,"twenty":-50.323187,"median":-43.65215,"eighty":-26.948338,"marketCap":15891673677},{"date":"2024-02-09","current":-43.972121,"twenty":-49.706536,"median":-43.780393,"eighty":-27.253528,"marketCap":18083628667},{"date":"2024-02-16","current":-51.156498,"twenty":-50.095577,"median":-43.99523,"eighty":-27.328768,"marketCap":21042767904},{"date":"2024-02-23","current":-57.052501,"twenty":-50.855188,"median":-44.095348,"eighty":-27.575851,"marketCap":23344320643},{"date":"2024-03-01","current":-55.517903,"twenty":-51.144997,"median":-44.174132,"eighty":-27.979787,"marketCap":22730573246},{"date":"2024-03-08","current":-62.556972,"twenty":-52.587613,"median":-44.308071,"eighty":-30.229554,"marketCap":25623953833},{"date":"2024-03-15","current":-80.340969,"twenty":-54.14227,"median":-44.794506,"eighty":-38.844663,"marketCap":32879324850},{"date":"2024-03-22","current":-87.812662,"twenty":-54.39157,"median":-45.089055,"eighty":-38.957109,"marketCap":35904222736},{"date":"2024-03-28","current":-54.646477,"twenty":-54.498503,"median":-45.202208,"eighty":-39.211798,"marketCap":33975302345},{"date":"2024-04-05","current":-48.790889,"twenty":-54.557693,"median":-45.399289,"eighty":-39.390336,"marketCap":30314737511},{"date":"2024-04-12","current":-51.407626,"twenty":-54.48688,"median":-46.006494,"eighty":-39.95604,"marketCap":31958703754},{"date":"2024-04-19","current":-48.134373,"twenty":-54.430626,"median":-46.386128,"eighty":-40.284427,"marketCap":29898266063},{"date":"2024-04-26","current":-71.709655,"twenty":-54.881886,"median":-46.751052,"eighty":-40.312191,"marketCap":36824843832},{"date":"2024-05-03","current":-70.050704,"twenty":-55.277405,"median":-46.894686,"eighty":-40.440284,"marketCap":35948061836},{"date":"2024-05-10","current":-80.537958,"twenty":-55.535893,"median":-47.299854,"eighty":-40.706984,"marketCap":41427949311},{"date":"2024-05-17","current":-72.846762,"twenty":-56.640749,"median":-47.434905,"eighty":-40.885351,"marketCap":37416671679},{"date":"2024-05-24","current":-76.490072,"twenty":-57.838988,"median":-47.480121,"eighty":-41.121673,"marketCap":39198277014},{"date":"2024-05-31","current":-74.804992,"twenty":-59.45269,"median":-48.0541,"eighty":-41.186166,"marketCap":38373753847},{"date":"2024-06-07","current":-77.551054,"twenty":-62.567703,"median":-48.422639,"eighty":-41.217553,"marketCap":39733102851},{"date":"2024-06-14","current":-71.048454,"twenty":-63.220056,"median":-48.609184,"eighty":-41.232055,"marketCap":36368156956},{"date":"2024-06-21","current":-75.38559,"twenty":-65.709636,"median":-48.654461,"eighty":-41.23344,"marketCap":38507460307},{"date":"2024-06-28","current":-72.361795,"twenty":-70.050704,"median":-48.790889,"eighty":-41.25919,"marketCap":36947551614},{"date":"2024-07-05","current":-71.32983,"twenty":-70.110492,"median":-48.913989,"eighty":-41.293743,"marketCap":36412725776},{"date":"2024-07-12","current":-64.338068,"twenty":-69.786991,"median":-49.290918,"eighty":-41.483815,"marketCap":32891789012},{"date":"2024-07-19","current":-64.816339,"twenty":-69.10708,"median":-50.290098,"eighty":-41.560643,"marketCap":33136917521},{"date":"2024-07-26","current":-64.836994,"twenty":-68.943217,"median":-50.396598,"eighty":-41.836002,"marketCap":33270623980},{"date":"2024-08-02","current":-67.177788,"twenty":-68.832021,"median":-50.583009,"eighty":-41.911922,"marketCap":34451697705},{"date":"2024-08-09","current":-67.337335,"twenty":-68.832021,"median":-50.91108,"eighty":-41.921641,"marketCap":34763679444},{"date":"2024-08-16","current":-69.468586,"twenty":-68.832021,"median":-51.098991,"eighty":-41.970061,"marketCap":35877899939},{"date":"2024-08-23","current":-143.952492,"twenty":-69.519081,"median":-51.282062,"eighty":-42.023931,"marketCap":36568716645},{"date":"2024-08-30","current":-142.905377,"twenty":-70.543671,"median":-51.775379,"eighty":-42.069838,"marketCap":36546432236},{"date":"2024-09-06","current":-147.713941,"twenty":-71.622574,"median":-52.451442,"eighty":-42.229208,"marketCap":37794359190},{"date":"2024-09-13","current":-159.71572,"twenty":-72.235174,"median":-53.058458,"eighty":-42.319371,"marketCap":40758185707},{"date":"2024-09-20","current":-153.295015,"twenty":-72.624329,"median":-53.663008,"eighty":-42.346401,"marketCap":39354267883},{"date":"2024-09-27","current":-152.378595,"twenty":-73.54444,"median":-54.299669,"eighty":-42.364187,"marketCap":39354267883},{"date":"2024-10-04","current":-188.785359,"twenty":-74.133327,"median":-54.381491,"eighty":-42.385888,"marketCap":48535444762},{"date":"2024-10-10","current":-168.292174,"twenty":-74.96999,"median":-54.488817,"eighty":-42.420555,"marketCap":42986626697},{"date":"2024-10-18","current":-169.261982,"twenty":-75.395206,"median":-54.742682,"eighty":-42.48514,"marketCap":43008911107},{"date":"2024-10-25","current":-173.131782,"twenty":-76.300948,"median":-55.181976,"eighty":-42.60999,"marketCap":43989425142},{"date":"2024-11-01","current":-155.135166,"twenty":-77.964709,"median":-55.298647,"eighty":-42.767052,"marketCap":39443405523},{"date":"2024-11-08","current":-154.553256,"twenty":-78.843611,"median":-55.532894,"eighty":-42.819467,"marketCap":38997717325},{"date":"2024-11-15","current":-143.716763,"twenty":-80.792913,"median":-56.569783,"eighty":-42.897746,"marketCap":35989321988},{"date":"2024-11-22","current":-149.571879,"twenty":-86.542136,"median":-57.071537,"eighty":-43.077872,"marketCap":37437808632},{"date":"2024-11-29","current":-163.214034,"twenty":-139.660525,"median":-57.926605,"eighty":-43.27892,"marketCap":40825038936},{"date":"2024-12-06","current":-164.492389,"twenty":-143.07608,"median":-58.601892,"eighty":-43.427612,"marketCap":41047883035},{"date":"2024-12-13","current":-167.859925,"twenty":-143.961595,"median":-59.46824,"eighty":-43.489321,"marketCap":41805552972},{"date":"2024-12-20","current":-160.518216,"twenty":-146.054141,"median":-61.493522,"eighty":-43.569737,"marketCap":39799956081},{"date":"2024-12-27","current":-154.616488,"twenty":-147.398806,"median":-62.556972,"eighty":-43.707223,"marketCap":38306900618},{"date":"2025-01-03","current":-146.467928,"twenty":-147.580179,"median":-62.909234,"eighty":-43.769457,"marketCap":36323588137},{"date":"2025-01-10","current":-149.189796,"twenty":-147.713941,"median":-63.270129,"eighty":-43.89543,"marketCap":36858413974},{"date":"2025-01-17","current":-146.545949,"twenty":-148.128618,"median":-63.821936,"eighty":-43.999852,"marketCap":36234450497},{"date":"2025-01-24","current":-151.096908,"twenty":-148.795989,"median":-64.223738,"eighty":-44.022873,"marketCap":37593799501},{"date":"2025-01-28","current":-144.751587,"twenty":-148.750633,"median":-64.3181,"eighty":-44.025895,"marketCap":36203787461},{"date":"2025-02-07","current":-162.755483,"twenty":-148.864023,"median":-64.816339,"eighty":-44.095348,"marketCap":40476425278},{"date":"2025-02-14","current":-166.856795,"twenty":-150.654332,"median":-65.202788,"eighty":-44.112421,"marketCap":41476404342},{"date":"2025-02-21","current":-194.414734,"twenty":-151.676932,"median":-65.382992,"eighty":-44.172115,"marketCap":48498984584},{"date":"2025-02-28","current":-211.14481,"twenty":-152.24965,"median":-65.712478,"eighty":-44.17615,"marketCap":52498900839},{"date":"2025-03-07","current":-225.41295,"twenty":-152.905086,"median":-66.309677,"eighty":-44.219461,"marketCap":56271549124},{"date":"2025-03-14","current":-227.151092,"twenty":-153.295015,"median":-66.812487,"eighty":-44.308071,"marketCap":56726085062},{"date":"2025-03-21","current":-236.708664,"twenty":-154.553256,"median":-67.337335,"eighty":-44.550078,"marketCap":59089671940},{"date":"2025-03-28","current":-231.805328,"twenty":-155.61149,"median":-67.803663,"eighty":-44.648429,"marketCap":66180441600},{"date":"2025-04-03","current":-246.46154,"twenty":-156.727441,"median":-67.952396,"eighty":-44.882152,"marketCap":70225812000},{"date":"2025-04-11","current":-242.489155,"twenty":-158.779779,"median":-68.515098,"eighty":-45.005591,"marketCap":68634936000},{"date":"2025-04-17","current":-228.611836,"twenty":-159.44307,"median":-68.80487,"eighty":-45.06217,"marketCap":64862287200}],"updateTime":1745156687961}}}